Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.36
28.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Additional Paid In Capital
Jiangsu Nhwa Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
|
Additional Paid In Capital
¥103m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
24%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Additional Paid In Capital
¥14.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Additional Paid In Capital
¥1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Additional Paid In Capital
¥3.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
21%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Additional Paid In Capital
¥17.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
30%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Additional Paid In Capital
¥858.7m
|
CAGR 3-Years
294%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
Glance View
Jiangsu Nhwa Pharmaceutical Co., Ltd. engages in the pharmaceutical production, research and development, and sales. The company is headquartered in Xuzhou, Jiangsu and currently employs 4,732 full-time employees. The company went IPO on 2008-07-23. The firm offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The firm is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Jiangsu Nhwa Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
103m
CNY
Based on the financial report for Jun 30, 2024, Jiangsu Nhwa Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 103m CNY.
What is Jiangsu Nhwa Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
24%
Over the last year, the Additional Paid In Capital growth was -14%. The average annual Additional Paid In Capital growth rates for Jiangsu Nhwa Pharmaceutical Co Ltd have been 26% over the past three years , -7% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
